Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers
References (52)
- et al.
Stem cells and cancer: two faces of eve
Cell
(2006) - et al.
The epithelial-mesenchymal transition generates cells with properties of stem cells
Cell
(2008) - et al.
Characterization of clonogenic multiple myeloma cells
Blood
(2004) - et al.
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
Cell Stem Cell
(2007) - et al.
EZH2 promotes expansion of breast tumour initiating cells through activation of RAF1-b-catenin signaling
Cancer Cell
(2011) - et al.
Triple-negative/basal-like breast cancer: review
Pathology
(2009) - et al.
Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumour markers
Am J Pathol
(2002) - et al.
In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis
Am J Pathol
(2010) - et al.
Predictive markers in breast cancer -the present
Histopathology
(2008) - et al.
Expression profiling technology: its contribution to our understanding of breast cancer
Histopathology
(2008)
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis
Nat Rev Cancer
Stem cells, cancer, and cancer stem cells
Nature
Cancer stem cells
N Engl J Med
Stem cells and breast cancer
Histopathology
Breast cancer stem cells and intrinsic subtypes: controversies rage on
Curr Stem Cell Res Ther
Cancer stem cells - perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells
Cancer Res
Cancer stem cells: implications for cancer treatment and prevention
Cancer J
Cancer stem cells: an old idea - a paradigm shift
Cancer Res
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Nat Rev Cancer
Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man?
Breast Cancer Res
Breast cancer stem cells: implications for therapy of breast cancer
Breast Cancer Res
Intrinsic resistance of tumourigenic breast cancer cells to chemotherapy
J Natl Cancer Inst
Are stem-like cells responsible for resistance to therapy in breast cancer?
Breast Dis
Cancer stem cells and radiotherapy: new insights into tumour radioresistance
J Natl Cancer Inst
Prospective identification of tumourigenic breast cancer cells
Proc Natl Acad Sci USA
Mammary stem cells, self-renewal pathways, and carcinogenesis
Breast Cancer Res
Cited by (34)
Nuclear aldehyde dehydrogenase 1A1 (ALDH1A1) expression is a favorable prognostic indicator in colorectal carcinoma
2016, Pathology Research and PracticeCitation Excerpt :Furthermore, other studies indicated that high cytoplasmic expression is a favorable prognostic factor in ovarian cancer [3], pancreatic cancer [10] and human hepatocellular carcinoma [23,25]. In addition to cytoplasmic expression, stromal expression has been assessed in breast cancer [5,20], and nuclear expression has been evaluated in colorectal and lung cancer [11,14]. Unfortunately, there is no agreement on its prognostic value.
Targeting breast cancer initiating cells: Advances in breast cancer research and therapy
2014, Advances in Biological RegulationCitation Excerpt :The expression of ALDH1 and the enhancer of zeste homolog 2 (EZH2) histone-lysine N-methyltransferase and other markers implicated in CICs including ER, PR, HER2, CK5, CK14, EGFR, TP63, caveolin, and TP53, were examined in 140 TNBC and basal-like breast cancers by a tissue microarray and immunohistochemistry. The expression of these markers and the clinicopathological features and patient outcomes were analyzed (De Brot et al., 2012). Cytoplasmic expression of ALDH1 was detected in 18.6% of the tumor samples while ALDH1 was observed in 83.6% of the stromal samples.
Novel prognostic markers for patients with triple-negative breast cancer
2013, Human PathologyCitation Excerpt :Cox-2 enzyme produces prostaglandins, which are involved in key processes in cancer development including cancer cell proliferation, resistance to apoptosis, mutagenesis, tumor angiogenesis, and invasion [5]. Cox-2 expression has been widely documented in invasive BC tissues and correlates with poor prognosis and progression of BC [11,9]. Controversially, Dhakal et al [12] revealed that expression of Cox-2 was not associated with BC-specific survival or disease-free survival for all patients.